91 related articles for article (PubMed ID: 19211266)
21. Serum levels of high-sensitivity troponin T: a novel marker for cardiac remodeling in hypertrophic cardiomyopathy.
Moreno V; Hernández-Romero D; Vilchez JA; García-Honrubia A; Cambronero F; Casas T; González J; Martínez P; Climent V; de la Morena G; Valdés M; Marín F
J Card Fail; 2010 Dec; 16(12):950-6. PubMed ID: 21111984
[TBL] [Abstract][Full Text] [Related]
22. Increased circulating matrix metalloproteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction.
Noji Y; Shimizu M; Ino H; Higashikata T; Yamaguchi M; Nohara A; Horita T; Shimizu K; Ito Y; Matsuda T; Namura M; Mabuchi H
Circ J; 2004 Apr; 68(4):355-60. PubMed ID: 15056834
[TBL] [Abstract][Full Text] [Related]
23. Growth differentiation factor-15, a novel biomarker related with disease severity in patients with hypertrophic cardiomyopathy.
Montoro-García S; Hernández-Romero D; Jover E; García-Honrubia A; Vilchez JA; Casas T; Martínez P; Climent V; Caballero L; Valdés M; Marín F
Eur J Intern Med; 2012 Mar; 23(2):169-74. PubMed ID: 22284249
[TBL] [Abstract][Full Text] [Related]
24. Continuous transthoracic echocardiography in a 93-year-old patient with hypertrophic cardiomyopathy during electroconvulsive therapy.
Robinson AR; Holbert R; Modell JH; Gravenstein N
J ECT; 2011 Sep; 27(3):224-6. PubMed ID: 21865958
[TBL] [Abstract][Full Text] [Related]
25. Assessment of mitral annulus size and function by real-time 3-dimensional echocardiography in cardiomyopathy: comparison with magnetic resonance imaging.
Anwar AM; Soliman OI; Nemes A; Germans T; Krenning BJ; Geleijnse ML; Van Rossum AC; ten Cate FJ
J Am Soc Echocardiogr; 2007 Aug; 20(8):941-8. PubMed ID: 17555937
[TBL] [Abstract][Full Text] [Related]
26. Pathogenesis of hypertrophic cardiomyopathy. Impact of growth factors on left ventricular anatomy.
Migliore T; Parrella LS; Caputi A; Silvestri N; Romano R; Pace L; Imbriaco M; Losi MA; Betocchi S
Minerva Cardioangiol; 2008 Feb; 56(1):13-20. PubMed ID: 18432164
[TBL] [Abstract][Full Text] [Related]
27. MRI of hypertrophic cardiomyopathy: part I, MRI appearances.
Hansen MW; Merchant N
AJR Am J Roentgenol; 2007 Dec; 189(6):1335-43. PubMed ID: 18029869
[TBL] [Abstract][Full Text] [Related]
28. Abnormal left ventricular contraction sequence in hypertrophic cardiomyopathy patients: first description of hypersynchrony and invert synchrony.
Duchateau J; Cornolle C; Peyrou J; Ritter P; Pillois X; Réant P; Reynaud A; Landelle M; Lafitte S
Ultrasound Med Biol; 2015 Jun; 41(6):1632-9. PubMed ID: 25747939
[TBL] [Abstract][Full Text] [Related]
29. Coronary vasodilator reserve is impaired in patients with hypertrophic cardiomyopathy and left ventricular dysfunction.
Lorenzoni R; Gistri R; Cecchi F; Olivotto I; Chiriatti G; Elliott P; McKenna WJ; Camici PG
Am Heart J; 1998 Dec; 136(6):972-81. PubMed ID: 9842009
[TBL] [Abstract][Full Text] [Related]
30. [Expression of monocyte chemoattractant protein-1 in sudden death due to viral myocarditis and its medicolegal significance].
Ning J; Li YH; Zhang CB
Fa Yi Xue Za Zhi; 2009 Oct; 25(5):334-6. PubMed ID: 20000039
[TBL] [Abstract][Full Text] [Related]
31. Apical segmental dysfunction in hypertrophic cardiomyopathy: progression into end-stage heart failure with sudden cardiac death.
Ko YL; Lin JL; Lei MH; Chen JJ; Tsou SS; Kuan P; Lien WP
Cardiology; 1995; 86(5):436-40. PubMed ID: 7585750
[TBL] [Abstract][Full Text] [Related]
32. Monocyte chemoattractant protein-1 in patients with peripheral arterial disease.
Petrkova J; Szotkowska J; Hermanova Z; Lukl J; Petrek M
Mediators Inflamm; 2004 Feb; 13(1):39-43. PubMed ID: 15203564
[TBL] [Abstract][Full Text] [Related]
33. Measurement of serum monocyte chemoattractant protein-1 and its clinical application for estimating the activity of granuloma formation in sarcoidosis.
Iyonaga K; Suga M; Ichiyasu H; Yamamoto T; Hiraga Y; Ando M
Sarcoidosis Vasc Diffuse Lung Dis; 1998 Sep; 15(2):165-72. PubMed ID: 9789895
[TBL] [Abstract][Full Text] [Related]
34. Systemic inflammation is associated with myocardial fibrosis, diastolic dysfunction, and cardiac hypertrophy in patients with hypertrophic cardiomyopathy.
Fang L; Ellims AH; Beale AL; Taylor AJ; Murphy A; Dart AM
Am J Transl Res; 2017; 9(11):5063-5073. PubMed ID: 29218105
[TBL] [Abstract][Full Text] [Related]
35. Low-grade systemic inflammation and left ventricular dysfunction in hypertensive compared to non-hypertensive hypertrophic cardiomyopathy.
Zach DK; Schwegel N; Santner V; Winkelbauer L; Hoeller V; Kolesnik E; Gollmer J; Seggewiss H; Batzner A; Perl S; Wallner M; Reiter U; Rainer PP; Zirlik A; Ablasser K; Verheyen N
Int J Cardiol; 2024 Mar; 399():131661. PubMed ID: 38158132
[TBL] [Abstract][Full Text] [Related]
36. Risk factors for systolic dysfunction and ventricular dilatation in hypertrophic cardiomyopathy.
Bingisser R; Candinas R; Schneider J; Hess OM
Int J Cardiol; 1994 May; 44(3):225-33. PubMed ID: 8077068
[TBL] [Abstract][Full Text] [Related]
37. Dilated phase of hypertrophic cardiomyopathy with mid-ventricular obstruction after 20-year follow-up.
Kawai M; Kihara Y; Hasegawa K; Matsumori A; Sasayama S
Jpn Circ J; 2000 Aug; 64(8):623-6. PubMed ID: 10952162
[TBL] [Abstract][Full Text] [Related]
38. Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry.
Gimeno JR; Olivotto I; Rodríguez AI; Ho CY; Fernández A; Quiroga A; Espinosa MA; Gómez-González C; Robledo M; Tojal-Sierra L; Day SM; Owens A; Barriales-Villa R; Larrañaga JM; Rodríguez-Palomares J; González-Del-Hoyo M; Piqueras-Flores J; Reza N; Chumakova O; Ashley EA; Parikh V; Wheeler M; Jacoby D; Pereira AC; Saberi S; Helms AS; Villacorta E; Gallego-Delgado M; de Castro D; Domínguez F; Ripoll-Vera T; Zorio-Grima E; Sánchez-Martínez JC; García-Álvarez A; Arbelo E; Mogollón MV; Fuentes-Cañamero ME; Grande E; Peña C; Monserrat L; Lakdawala NK;
ESC Heart Fail; 2022 Aug; 9(4):2189-2198. PubMed ID: 36255281
[TBL] [Abstract][Full Text] [Related]
39. Circulating mesenchymal stem cells in patients with hypertrophic cardiomyopathy.
Marketou ME; Parthenakis FI; Kalyva A; Pontikoglou C; Maragkoudakis S; Kontaraki JE; Zacharis EA; Patrianakos A; Chlouverakis G; Papadaki HA; Vardas PE
Cardiovasc Pathol; 2015; 24(3):149-53. PubMed ID: 25744383
[TBL] [Abstract][Full Text] [Related]
40. In active juvenile dermatomyositis, elevated eotaxin and MCP-1 and cholesterol levels in the upper normal range are associated with cardiac dysfunction.
Schwartz T; Sjaastad I; Flatø B; Vistnes M; Christensen G; Sanner H
Rheumatology (Oxford); 2014 Dec; 53(12):2214-22. PubMed ID: 24996906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
